Drug name - Aristada
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) | |
| US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(8 years from now) | |
| EP2445502B1 | ALKERMES INC | Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders |
Jun, 2030
(7 years from now) | |
| EP2445502A1 | ALKERMES INC | Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders |
Jun, 2030
(7 years from now) | |
| EP2445343A1 | ALKERMES INC | Prodrugs Of Nh-Acidic Compounds |
Jun, 2030
(7 years from now) | |
| EP2445343B1 | ALKERMES INC | Prodrugs Of Nh-Acidic Compounds |
Jun, 2030
(7 years from now) | |
| EP2445502A4 | ALKERMES INC | Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders |
Jun, 2030
(7 years from now) | |
| EP2445343A4 | ALKERMES INC | Prodrugs Of Nh-Acidic Compounds |
Jun, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) | |
| US10226458 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Mar, 2032
(9 years from now) | |
| US9034867 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Nov, 2032
(10 years from now) | |
| US11097006 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(11 years from now) | |
| US9193685 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(11 years from now) | |
| US9526726 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US10238651 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US10813928 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
| US9452131 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(12 years from now) | |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Treatment: Treatment of schizophrenia; Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous intramuscular injection; treatment of schizophrenia by rapid and continuous injection
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
| Strength | Dosage | Availability |
|---|---|---|
| 441MG/1.6ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 662MG/2.4ML (275.83MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 882MG/3.2ML (275.63MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
| 1064MG/3.9ML (272.82MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.